Table 1.
Demographic, genetic, pathologic, and clinical characteristics of participants grouped by TDP-43 stage
| Characteristic | T0 | T1 | T2 | Overalla | T0/T1 | T0/T2 | T1/T2 |
| n = 260 | n = 32 | n = 93 | p | p | p | p | |
| Female, n (%) | 131 (50%) | 17 (53%) | 58 (62%) | 0.13 | |||
| APOE ɛ4 carrier, n (%) | 71 (27%) | 16 (50%) | 36 (39%) | 0.01 | 0.01 | 0.048 | 0.30 |
| Amyloid- β, CERAD, n (%) | < 0.001 | 0.005 | < 0.001 | 0.61 | |||
| C0 | 81 (31%) | 7 (22%) | 15 (16%) | ||||
| C1 | 65 (25%) | 3 (9%) | 16 (17%) | ||||
| C2 | 66 (25%) | 7 (22%) | 25 (27%) | ||||
| C3 | 48 (18%) | 15 (47%) | 37 (40%) | ||||
| Tau, Braak NFT stage, n (%) | < 0.001 | < 0.001 | < 0.001 | 0.38 | |||
| 0 | 5 (2%) | 0 (0%) | 0 (0%) | ||||
| I | 22 (8%) | 1 (3%) | 3 (3%) | ||||
| II | 60 (23%) | 6 (19%) | 8 (9%) | ||||
| III | 49 (19%) | 2 (6%) | 11 (12%) | ||||
| IV | 59 (23%) | 4 (12%) | 18 (19%) | ||||
| V | 49 (19%) | 6 (19%) | 26 (28%) | ||||
| VI | 16 (6%) | 13 (41%) | 27 (29%) | ||||
| Lewy body disease stage, n (%) | 0.003 | 0.17 | 0.001 | 0.30 | |||
| 0 | 207 (80%) | 22 (71%) | 55 (60%) | ||||
| 1 | 10 (4%) | 0 (0%) | 4 (4%) | ||||
| 2 | 27 (10%) | 6 (19%) | 17 (18%) | ||||
| 3 | 16 (6%) | 3 (10%) | 16 (17%) | ||||
| Vascular score, n (%) | 0.58 | ||||||
| 0 | 133 (51%) | 18 (56%) | 48 (52%) | ||||
| 1 | 97 (37%) | 10 (31%) | 39 (42%) | ||||
| 2 | 30 (12%) | 4 (12%) | 6 (6%) | ||||
| Diagnosis at last exam, n (%) | < 0.001 | 0.003 | < 0.001 | 0.68 | |||
| CU | 148 (57%) | 10 (31%) | 20 (22%) | ||||
| MCI | 49 (19%) | 5 (16%) | 14 (15%) | ||||
| AD | 41 (16%) | 14 (44%) | 45 (48%) | ||||
| Other | 22 (8%) | 3 (9%) | 14 (15%) | ||||
| Age at clinical exam, y | |||||||
| Baseline | 81 (44, 98) | 76 (59, 97) | 81 (54, 95) | 0.054 | |||
| Last | 87 (53, 102) | 83 (69, 105) | 88 (60, 101) | 0.02 | 0.10 | 0.04 | 0.01 |
| Years from baseline to death | 7.1 (0.3, 22.4) | 8.0 (2.6, 16.6) | 9.9 (1.3, 18.2) | < 0.001 | 0.35 | < 0.001 | 0.03 |
| No. of visits | 4.5 (1.0, 15.0) | 5.5 (2.0, 14.0) | 6.0 (1.0, 14.0) | < 0.001 | 0.10 | < 0.001 | 0.36 |
| 2 | 30 (12%) | 4 (12%) | 6 (6%) | ||||
| 3 | 42 (16%) | 4 (12%) | 7 (8%) | ||||
| 4 | 37 (14%) | 4 (12%) | 7 (8%) | ||||
| > 4 | 130 (50%) | 20 (62%) | 69 (74%) |
Data shown are n (%) or median (range). ap-values for continuous variables are from Wilcoxon rank sum test or ANOVA; p-values for categorical variables are from Fisher’s Exact test. CU, cognitively unimpaired; MCI, mild cognitive impairment; AD, Alzheimer’s disease.